0000950170-23-069496.txt : 20231211
0000950170-23-069496.hdr.sgml : 20231211
20231211200003
ACCESSION NUMBER: 0000950170-23-069496
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231211
FILED AS OF DATE: 20231211
DATE AS OF CHANGE: 20231211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Astle Christopher
CENTRAL INDEX KEY: 0001915257
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41535
FILM NUMBER: 231479729
MAIL ADDRESS:
STREET 1: 114 EAST 4TH AVENUE, SUITE 800
CITY: VANCOUVER
STATE: A1
ZIP: V5T 1G4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zymeworks Inc.
CENTRAL INDEX KEY: 0001937653
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 108 PATRIOT DRIVE, SUITE A
CITY: MIDDLETOWN
STATE: DE
ZIP: 19709
BUSINESS PHONE: 206-337-1030
MAIL ADDRESS:
STREET 1: 108 PATRIOT DRIVE, SUITE A
CITY: MIDDLETOWN
STATE: DE
ZIP: 19709
FORMER COMPANY:
FORMER CONFORMED NAME: Zymeworks Delaware Inc.
DATE OF NAME CHANGE: 20220712
4
1
ownership.xml
4
X0508
4
2023-12-11
0001937653
Zymeworks Inc.
ZYME
0001915257
Astle Christopher
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN
DE
19709
false
true
false
false
SVP & Chief Financial Officer
false
Common Stock
2023-12-11
4
M
false
1550
0.00
A
2883
D
Common Stock
2023-12-11
4
S
false
886
9.1301
D
1997
D
Restricted Stock Unit
2023-12-11
4
M
false
1550
0.00
D
Common Stock
1550
0
D
Represents shares of common stock issued upon vesting of one half of the restricted stock units ("RSUs") granted on December 10, 2021.
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.11 to $9.16, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
The RSUs were granted on December 10, 2021 and vested in two equal annual instalments (on December 12, 2022 and December 11, 2023).
/s/ Daniel Dex, Attorney-in-Fact
2023-12-11